Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib for Early Lung Dysfunction After HSCT
NCT04908735Phase 2Terminated
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Nov 2021
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in Bronchiolitis Obliterans (BO), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoint: Number of participants with ruxolitinib treatment response at 6 months. Started Nov 2021; status: terminated.
02
Drugs
03
Conditions
Bronchiolitis Obliterans (BO)
Beyond the preview
Go deeper on NCT04908735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04908735.